ArticleClinical, cosmetic and investigational dermatology2026
Rapid Improvement of Acute Eczematous Facial Dermatitis During Pregnancy Following Stapokibart Therapy: A Case Report.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stapokibart for Facial-Predominant AD-Like Dermatoses: A Retrospective Real-World Case Series Highlighting Response Heterogeneity.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute eczematous facial dermatitis can cause erythema, edema, and severe pruritus, with marked effects on sleep and quality of life. Treatment during pregnancy is challenging because therapeutic options are limited by safety concerns. Case Presentation: This single case report describes a 35-year-old pregnant woman at 9 weeks' gestation who presented with a 10-day history of progressive facial erythema, swelling, and severe pruritus. She had recurrent facial dermatitis, allergic rhinitis, and asthma, supporting an atopic background. Antihistamines and topical corticosteroids were ineffective. Acute eczematous facial dermatitis with atopic features was considered. After risk-benefit assessment and informed consent, stapokibart was initiated with a 600 mg loading dose followed by 300 mg on day 10. Results: Pruritus became minimal within 3 days after the first injection. By day 10, facial erythema and edema had markedly improved; by day 31, the lesions had nearly resolved. EASI decreased from 4.2 to 2 and 1 at day 10 and day 31, respectively; IGA improved from 4 to 2 and 0; pruritus NRS decreased from 8-9 to 3-4 and 0; and DLQI improved from 25 to 7 and 2. No treatment-related adverse events were reported during short-term follow-up. At the time of manuscript preparation, the pregnancy was ongoing at 18 weeks' gestation, with normal prenatal ultrasonography and no reported obstetric complications. Conclusion: Stapokibart may provide rapid short-term improvement in selected patients with acute eczematous facial dermatitis with atopic features during pregnancy. During short-term follow-up to 18 weeks' gestation, no treatment-related adverse events or obstetric complications were reported. However, no conclusions regarding maternal or fetal safety can be drawn from this single case, and continued follow-up is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.